



Suggested Formula	Mupirocin 2% Nasal Ointment (Emulsion, 50 g)	FIN	F 006 938v2
-------------------	--	-----	-------------

### SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Mupirocin Calcium, USP	TBD					
Mineral Oil (Light), NF	5.0	mL				
Medisca OleaBase™ Plasticized	TBD					

### SPECIAL PREPARATORY CONSIDERATIONS

#### Ingredient-Specific Information

*Light sensitive (protect from light whenever possible):*

*Mineral Oil*

#### Suggested Preparatory Guidelines

Non-Sterile Preparation     Sterile Preparation

#### Processing Error /

#### Testing Considerations:

To account for processing error and sterility testing considerations during preparation, it is suggested to measure an additional **10 to 12%** of the required quantities of ingredients.

#### Special Instruction:

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 797*. Only trained and qualified personnel must prepare this formula.

All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use.

Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed.

Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, eyewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area.

Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Mupirocin 2% Nasal Ointment (Emulsion, 50 g)	FIN	F 006 938v2
-------------------	--	-----	-------------

**SUGGESTED PREPARATION (for 50 g)**

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): _____	Processing Error	Qty. to measure
Mupirocin Calcium, USP	TBD				
Mineral Oil (Light), NF §	5.0	mL			
Medisca OleaBase™ Plasticized	TBD				

§ Weigh / measure just prior to use.

\* Takes into account increased batch size conversions and density conversions, if required.

Preparatory Instruction

**IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique**

1. **Ingredient quantification:**

A. Determine the quantity (in g) of Mupirocin Calcium required to make a **Mupirocin** 2% Nasal Ointment, batch size (50 g):

Quantity of Mupirocin required for 50 g	1000 mg
DIVIDED BY	
Assay (base equivalent) on anhydrous basis result (from certificate of analysis: µg/mg = mg/g)	_____ µg/mg
EQUALS	
<b>i. Quantity of Mupirocin Calcium needed for 50 g</b>	_____ g
MULTIPLIED BY	
Processing error adjustments (10 to 12%)	1.10 to 1.12
EQUALS	
<b>ii. Quantity of Mupirocin Calcium needed plus processing error adjustments</b>	_____ g



Suggested Formula	Mupirocin 2% Nasal Ointment (Emulsion, 50 g)	FIN	F 006 938v2
-------------------	--	-----	-------------

2.	<p><b><u>Ingredient quantification:</u></b></p> <p>A. Determine the actual quantity of OleaBase™ Plasticized to weigh for the required batch size (50 g):</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td>Total Weight of the batch</td> <td style="text-align: right;">50 g</td> </tr> <tr> <td>MINUS</td> <td></td> </tr> <tr> <td>The amount of other ingredient except Mupirocin Calcium</td> <td style="text-align: right;">4.245 g</td> </tr> <tr> <td>MINUS</td> <td></td> </tr> <tr> <td>The weight of Mupirocin Calcium (Step 1Ai)</td> <td style="text-align: right;">_____ g</td> </tr> <tr> <td>EQUALS</td> <td></td> </tr> <tr> <td><b>i. Quantity of OleaBase™ Plasticized needed for 50 g</b></td> <td style="text-align: right;">_____ g</td> </tr> <tr> <td>MULTIPLIED BY</td> <td></td> </tr> <tr> <td>Processing error adjustments (10 to 12%)</td> <td style="text-align: right;">1.10 to 1.12</td> </tr> <tr> <td>EQUALS</td> <td></td> </tr> <tr> <td><b>ii. Weight of OleaBase™ Plasticized required <i>plus</i> processing error adjustments</b></td> <td style="text-align: right;">_____ g</td> </tr> </table>	Total Weight of the batch	50 g	MINUS		The amount of other ingredient except Mupirocin Calcium	4.245 g	MINUS		The weight of Mupirocin Calcium (Step 1Ai)	_____ g	EQUALS		<b>i. Quantity of OleaBase™ Plasticized needed for 50 g</b>	_____ g	MULTIPLIED BY		Processing error adjustments (10 to 12%)	1.10 to 1.12	EQUALS		<b>ii. Weight of OleaBase™ Plasticized required <i>plus</i> processing error adjustments</b>	_____ g
Total Weight of the batch	50 g																						
MINUS																							
The amount of other ingredient except Mupirocin Calcium	4.245 g																						
MINUS																							
The weight of Mupirocin Calcium (Step 1Ai)	_____ g																						
EQUALS																							
<b>i. Quantity of OleaBase™ Plasticized needed for 50 g</b>	_____ g																						
MULTIPLIED BY																							
Processing error adjustments (10 to 12%)	1.10 to 1.12																						
EQUALS																							
<b>ii. Weight of OleaBase™ Plasticized required <i>plus</i> processing error adjustments</b>	_____ g																						
3.	<p><b><u>Sterilization:</u></b></p> <p>Following the manufacturer’s specifications, autoclave sterilize the OleaBase™ Plasticized (amount determined in Step 2Aii), then return to ambient temperature and pressure.</p> <p><u>Specifications:</u></p> <p>Heating temperature: 121°C      Heating time: 30 minutes      Pressure: 15 psi</p> <p><b><u>IMPORTANT:</u></b> The temperature of the heated chamber must reach 121°C before the exposure duration is timed.</p>																						
4.	<p><b><u>Powder-liquid preparation:</u></b></p> <p>A. Aseptically filter the Mineral Oil (Light) through a 0.22-µm sterile filter into Mupirocin Calcium (amount determined in Step 1Aii) and levigate the mixture into a homogeneous liquid-like dispersion.</p>																						



Suggested Formula	Mupirocin 2% Nasal Ointment (Emulsion, 50 g)	FIN	F 006 938v2
-------------------	--	-----	-------------

5.	<p><b><u>Powder-liquid to medium integration:</u></b></p> <p>A. Incrementally add the homogeneous liquid-like dispersion (Step 4A) to the Sterilized OleaBase™ Plasticized (Step 3).</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous ointment-like dispersion.</p>
6.	<p><b><u>Microbial Enumeration testing:</u></b></p> <p>Test the product for microbial count and specified microorganisms to meet the requirements for Mupirocin Nasal Ointment, in accordance to current USP &lt;61&gt; and &lt;62&gt; procedures.</p>
7.	<p><b><u>Product transfer:</u></b></p> <p>Transfer the final product into the specified dispensing container (see “Packaging requirements”).</p>

**SUGGESTED PRESENTATION**

Estimated Beyond-Use Date	30 days, as per USP.	Packaging Requirements	- Tightly closed, light-resistant ointment tube/jar. - To be administered with a metered-dose measuring device.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	5	Protect from light.
	2	Keep out of reach of children.	6	Cap tightly after use.
	3	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	7	For nasal use only.
	4	Keep at room temperature (20°C – 23°C).		
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions. <b>IMPORTANT:</b> The quantity of API administered is directly dependent on the quantity of product applied.			



Suggested Formula	Mupirocin 2% Nasal Ointment (Emulsion, 50 g)	FIN	F 006 938v2
-------------------	--	-----	-------------

## REFERENCES

1.	Ophthalmic, Otic, and Nasal Preparations. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition</i> . American Pharmaceutical Association; 2012: 307.
2.	Mupirocin Calcium. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36<sup>th</sup> Edition</i> . London, England: The Pharmaceutical Press; 2009: 302.
3.	Mupirocin (Monograph). In: O'Neil MJ. <i>The Merck Index 15<sup>th</sup> Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: #6388.
4.	Mupirocin. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5<sup>th</sup> Edition</i> . American Pharmaceutical Association; 2012: 344.
5.	Mupirocin Calcium (Monograph). <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 4953.
6.	USP <797>. <i>United States Pharmacopeia XXXIX / National Formulary 34</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2016: 626.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.